Key Highlights
- Sun Pharmaceutical Industries has reached an agreement to acquire Organon & Co through an all-cash transaction that values the pharmaceutical company at $11.75 billion, debt included.
- Shareholders of Organon will be paid $14.00 per share in cash.
- Shares of Organon jumped approximately 31% on Friday following initial media reports, then gained an additional ~15% during Monday’s premarket session.
- The merged entity is projected to become one of the world’s top 25 pharmaceutical companies, generating pro forma revenues of $12.4 billion.
- Completion of the transaction is anticipated in early 2027, contingent upon regulatory clearances and shareholder consent.
Sun Pharma, recognized as India’s leading pharmaceutical manufacturer, revealed on Sunday its intention to purchase New Jersey-headquartered Organon & Co in an entirely cash-based transaction totaling $11.75 billion with debt. Shareholders will receive $14.00 for each share they hold.
Shares of Organon had already experienced a substantial rally of nearly 31% on Friday when the Economic Times initially disclosed that Sun Pharma was engaged in acquisition discussions for a price tag around $13 billion. Following Sunday’s formal announcement, Organon shares climbed another ~15% during early Monday premarket activity.
The cumulative price movement across both trading sessions represents an approximately 46% increase from pre-announcement levels.
Organon emerged as an independent entity after being separated from Merck in 2021, concentrating on women’s healthcare products, biosimilar medications, and established brand-name pharmaceuticals. The company generated $6.2 billion in revenue and $1.9 billion in adjusted EBITDA during 2025.
Sun Pharma indicated it will finance the acquisition through available cash reserves and secured bank credit facilities. The transaction has received approval from both companies’ boards of directors.
Strategic Benefits for Sun Pharma
This acquisition provides Sun Pharma with immediate access to a portfolio exceeding 70 pharmaceutical products distributed across more than 140 nations. The transaction also positions the Indian pharmaceutical giant in the biosimilars market, where the combined organization would rank as the seventh-largest competitor worldwide.
Organon maintains significant market presence in the United States, European Union, China, Canada, and Brazil. The company manages six production facilities located throughout the EU and developing markets.
Macquarie analyst Dr. Kunal characterized the acquisition as “strategically and financially compelling” for Sun. He highlighted that the merged company will derive 27% of revenues from innovative pharmaceutical products, an increase from Sun Pharma’s current 20% standalone figure.
Sun Pharma presently maintains operations in dermatology, ophthalmology, and onco-dermatology within its innovative medicines division. The addition of Organon’s women’s health product line would substantially broaden that therapeutic scope.
The combined organization would also secure a position among the top three competitors in the global women’s health pharmaceutical sector.
Financial Considerations and Debt Profile
Organon entered this transaction with $8.6 billion in outstanding debt obligations and cash reserves of $574 million as of December 2025. The company’s net debt to EBITDA multiple was positioned at 4 times prior to the deal announcement.
Sun Pharma, in contrast, maintained a net cash-positive balance sheet before this acquisition. Following transaction completion, the consolidated entity is forecast to operate with a net debt to EBITDA ratio of 2.3 times.
Bhavesh Shah of Equirus Capital observed that such transactions can deliver “value accretive over the medium to long term,” though he cautioned about near-term headwinds including integration expenses and operational execution obstacles.
This marks the sixth major acquisition executed by Sun Pharma over the past 16 years. Previous transactions include the 2007 purchase of financially troubled Israeli company Taro Pharma and the 2014 acquisition of Ranbaxy Laboratories for approximately $3.2 billion.
The Organon acquisition is projected to elevate Sun Pharma into the ranks of the top 25 global pharmaceutical corporations, with combined pro forma revenues reaching $12.4 billion.
The deal is scheduled to finalize in early 2027, pending successful completion of regulatory reviews and shareholder voting processes.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
